Case | Diagnostic opportunity | SpO2a) (%) | KL-6a) (U/mL) | Gradeb) | CT findings | BAL and its diagnosis | Therapy for ILD |
---|
1 | Continuous pyrexia | 97 | 316 | 2 | HR | Done, PCP | PSL + TMP/SMX |
2 | Continuous pyrexia | 98 | 468 | 1 | HR | Done, Negative | None |
3 | High KL-6, low SpO2 | 94 | 716 | 2 | HR | None | PSL |
4 | E-CTc), low SpO2 | 94 | 338 | 2 | OP | None | PSL |
5 | E-CT | 98 | 346 | 2 | HR | Done, PCP | TMP/SMX |
- ILD interstitial lung disease, SpO2 percutaneous oxygen saturation, KL-6 serum Krebs von den Lungen-6, CT computed tomography, BAL bronchoalveolar lavage sampling, HR hypersensitivity reaction-like pattern, PCP Pneumocystis jiroveci pneumonia, PSL orally prednisolone (a day), TMP/SMX orally trimethoprim-sulfamethoxazole (a day), OP organizing pneumonia-like pattern
- aValues were at the onset of ILD. Standard value; SpO2 ≥ 95%, KL-6 < 500 U/mL
- bILD (pneumonitis) grade as in common terminology criteria for adverse events 5.0
- cCT to estimate the anti-cancer effect after epirubicin and cyclophosphamide